High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines
Metrics: PDF 1074 views | HTML 1503 views | ?
Farhad Ghasemi1,*, Morgan Black1,2,*, Ren X. Sun3,4, Frederick Vizeacoumar5, Nicole Pinto1,2, Kara M. Ruicci1,2, John Yoo1,2, Kevin Fung1,2, Danielle MacNeil1,2, David A. Palma2, Eric Winquist2, Joe S. Mymryk1,2,6, Laurie A. Ailles7, Alessandro Datti8,9, John W. Barrett1,2,**, Paul C. Boutros3,4,7,** and Anthony C. Nichols1,2,**
1Department of Otolaryngology – Head and Neck Surgery, London Health Sciences Centre, London, Ontario, Canada
2Department of Oncology, London Health Sciences Centre, London, Ontario, Canada
3Ontario Institute of Cancer Research, MaRS Centre, Toronto, Ontario, Canada
4Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada
5Cancer Research Cluster, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
6Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada
7Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
8Network Biology Collaborative Centre, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
9Department of Agricultural, Food, and Environmental Sciences, University of Perugia, Perugia, Italy
*These authors have contributed equally to this paper
**These authors have contributed equally to this paper
Anthony C. Nichols, email: Anthony.Nichols@lhsc.on.ca
Keywords: head and neck cancer; human papillomavirus; high throughput drug testing; cell lines; chemotherapy
Abbreviations: HNSCC: Head and Neck Squamous Cell Carcinoma; HPV: Human papillomavirus; IC50: half-maximal inhibitory concentration
Received: February 08, 2018 Accepted: April 28, 2018 Published: May 25, 2018
Head and neck squamous cell carcinoma (HNSCC) is a common cancer diagnosis worldwide. Despite advances in treatment, HNSCC has very poor survival outcomes, emphasizing an ongoing need for development of improved therapeutic options. The distinct tumor characteristics of human papillomavirus (HPV)-positive vs. HPV-negative disease necessitate development of treatment strategies tailored to tumor HPV-status. High-throughput robotic screening of 1,433 biologically and pharmacologically relevant compounds at a single dose (4 μM) was carried out against 6 HPV-positive and 20 HPV-negative HNSCC cell lines for preliminary identification of therapeutically relevant compounds. Statistical analysis was further carried out to differentiate compounds with preferential activity against cell lines stratified by the HPV-status. These analyses yielded 57 compounds with higher activity in HPV-negative cell lines, and 34 with higher-activity in HPV-positive ones. Multi-point dose-response curves were generated for six of these compounds (Ryuvidine, MK-1775, SNS-032, Flavopiridol, AZD-7762 and ARP-101), confirming Ryuvidine to have preferential potency against HPV-negative cell lines, and MK-1775 to have preferential potency against HPV-positive cell lines. These data comprise a valuable resource for further investigation of compounds with therapeutic potential in the HNSCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.